Edgewise Therapeutics, Inc. (EWTX) Stock

HealthcareBiotechnology Website

4 of the hedge funds AlphaScala tracks reported EWTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $19.08M. Company insiders reported 0 open-market buys and 19 sales on SEC Form 4 in the 90 days to Oct 21, 2026.

Which hedge funds own EWTX?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Citadel
Ken Griffin
470K$19.08M+9%
D.E. Shaw
David Shaw
189K$7.68M+80%
Point72
Steve Cohen
117K$4.76MNEW
Marshall Wace6K$247.8K-99%

13F holdings as of Jun 30, 2026

Explore all tracked funds →

Are Edgewise Therapeutics, Inc. insiders buying or selling?

SEC Form 4 filings
90 days to Oct 21, 2026
Buys
0
Sells
19
Net $
-$1.9M
Unique insiders
5
DateInsiderRoleTypeSharesValue
Aug 13, 26Donovan Joanne M.CMOSELL2.9K$127K
Aug 12, 26Koch KevinPresident and CEOSELL8.8K$383K
Aug 12, 26Koch KevinPresident and CEOSELL8.3K$361K
Aug 12, 26Koch KevinPresident and CEOSELL913$40K
Aug 12, 26Moore John RGeneral CounselSELL2.4K$107K
Aug 12, 26Moore John RGeneral CounselSELL59$3K
Aug 12, 26Moore John RGeneral CounselSELL99$4K
Aug 12, 26Moore John RGeneral CounselSELL2.4K$106K
Aug 12, 26Donovan Joanne M.CMOSELL2.8K$124K
Aug 12, 26Donovan Joanne M.CMOSELL2.8K$121K

SEC Form 4 filings as of Oct 21, 2026

See cluster-buy signals across all tickers →

EWTX price chart

Powered by TradingView

What does Edgewise Therapeutics, Inc. do?

Edgewise Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies targeting rare muscle disorders. The company's primary function is to address unmet medical needs in the area of muscular health, specifically aiming to develop treatments for conditions such as Duchenne muscular dystrophy. Edgewise Therapeutics employs a cutting-edge approach by utilizing small molecule drugs to modulate proteins critical to muscle function and health. Operating within the biopharmaceutical industry, Edgewise is part of a niche sector where advancements can lead to significant improvements in patient care. Their efforts contribute to the broader medical and pharmaceutical markets by potentially offering new therapeutic options that can have a profound impact on patients' lives. Market significance is underscored by the ongoing need for effective treatments for rare diseases, which often lack adequate therapeutic solutions. Edgewise Therapeutics is an example of how specialized research and development can drive innovation in healthcare, seeking to transform scientific advancements into life-changing medications.

CEO
Dr. Kevin Koch Ph.D.
Employees
146
Ask about EWTXAI research agent